Frauenfeld, 15 October 2026

Press release
Ad hoc announcement pursuant to Art. 53 LR

DocMorris accelerates Rx growth to 78% in Q3; EBITDA breakeven already achieved in Q3 and revenue and EBITDA forecast for 2026 raised again

• Revenue growth of 21.5% in Q3 and 15.5% in the first nine months
• Strong acceleration of Rx growth to 78.3% versus Q3 2025; plus 33.5% versus Q2 2026
• Non-Rx up 5.5% in Q3, of which Digital Services up 46.1%
• Adjusted EBITDA of CHF 0.6 million in Q3
• Revenue and adjusted EBITDA guidance for 2026 increased

CEO Walter Hess says: “Our revenue growth accelerated again in the third quarter of 2026, demonstrating that our offering is well received by patients. We will continue to consistently leverage this Rx momentum to expand our customer base and further solidify our position in the digital healthcare market.”

CFO Daniel Wüest adds: “Thanks to the strong performance of Rx and Digital Services, as well as further improvements in cost and marketing efficiency, we already achieved our targeted EBITDA breakeven in the third quarter with adjusted EBITDA of CHF 0.6 million. Against this backdrop, we are once again raising our revenue and EBITDA guidance for the full year.”

Significantly accelerated Rx growth in the third quarter

• DocMorris increased its external revenue[1] in the third quarter of 2026 significantly by 21.5 per cent[2] year-on-year to CHF 342.7 million, while revenue increased by 22.2 per cent to CHF 327.4 million.
• In the segment Germany, external revenue increased by 22.0 per cent.
• External revenue growth for prescription medicines (Rx) accelerated in the third quarter to 78.3 per cent year-on-year; Rx external revenue was 33.5 per cent higher than in the already strong second quarter of 2026 (up 17.0 per cent in Q2 compared to Q1 2026).
• Non-Rx[3] external revenue increased by 5.5 per cent.
• The OTC business grew as planned by 3.5 per cent.
• Digital Services, comprising TeleClinic, Retail Media and Marketplace, achieved revenue growth of 46.1 per cent to CHF 13.9 million, with a further increase in earnings contribution.
• In the segment Europe, revenue increased by 12.0 per cent.
• The number of active customers[4] increased year-on-year by 1.5 million to 13.1 million. Of these, 0.2 million were added in the third quarter of 2026, with the number of new Rx customers increasing at an above-average rate.
• DocMorris achieved an adjusted EBITDA of CHF 0.6 million in the third quarter, thus reaching the targeted breakeven ahead of schedule.

Continued double-digit growth in the first nine months

• External revenue increased by 15.5 per cent to CHF 970.6 million in the first nine months of 2026 year-on-year, while revenue increased by 16.4 per cent to CHF 926.6 million.
• In the segment Germany, external revenue increased by 16.0 per cent.
• Rx growth amounted to 52.6 per cent in the first nine months, with a continued positive trend in the fourth quarter.
• Non-Rx increased by 6.2 per cent, with Digital Services growing by 62.0 per cent to CHF 41.0 million.
• In the segment Europe, revenue increased by 6.3 per cent.

In September 2026, DocMorris successfully repurchased its CHF 49.6 million convertible bond maturing in 2028. The repurchase was financed by issuing a new convertible bond maturing in 2031. This move extends the company’s maturity profile while simultaneously reducing its relative financing costs.

Outlook
Due to continued positive current trading, DocMorris is raising its guidance for 2026 again as follows:

• External revenue growth: 12.5 to 15 per cent (previously: 9 to 13 per cent);
• Adjusted EBITDA: Better than minus CHF 10 million (previously: minus CHF 10 million to minus CHF 17.5 million);
• Capital expenditure remains unchanged at below CHF 30 million.

Management confirms the target of achieving free cash flow breakeven during 2027, following the achievement of the adjusted EBITDA breakeven target during 2026 in the third quarter. Medium-term targets remain unchanged.

 

Key figures, in million CHF (unaudited)	Q3 2026	Q3 2025	Change	Change in local currency
DocMorris external revenue	342.7	282.3	21.4%	21.5%
DocMorris revenue	327.4	268.1	22.1%	22.2%
Markets
Germany external revenue	326.3	267.6	21.9%	22.0%
Germany revenue	311.0	253.5	22.7%	22.8%
Germany Rx external revenue	108.1	60.9	77.6%	78.3%
Germany non-Rx external revenue	218.2	206.8	5.5%	5.5%
Europe revenue	16.4	14.6	11.9%	12.0%

 

Key figures, in million CHF (unaudited)	9M 2026	9M 2025	Change	Change in local currency
DocMorris external revenue	970.6	854.3	13.6%	15.5%
DocMorris revenue	926.6	809.4	14.5%	16.4%
Markets
Germany external revenue	920.3	806.2	14.1%	16.0%
Germany revenue	876.4	761.3	15.1%	17.0%
Germany Rx external revenue	256.0	170.5	50.1%	52.6%
Germany non-Rx external revenue	664.2	635.7	4.5%	6.2%
Europe revenue	50.3	48.1	4.6%	6.3%

 

Investors and analyst contact
Kelvin Jörn, Head of Investor Relations
Email: ir@docmorris.com, phone: +41 52 560 58 10

Media contact
Torben Bonnke, Director Communications
Email: media@docmorris.com, phone: +49 171 864 888 1

Agenda

12 November 2026	Capital Markets Day in Heerlen (NL)
19 January 2027	Revenue 2026
18 March 2027	2026 Full-year results and outlook 2027 (hybrid/Zurich, conference call/webcast)
15 April 2027	Q1/2027 Trading Update
12 May 2027	Annual General Meeting, Zurich

 

DocMorris
The Swiss-based DocMorris AG is a leading company in the fields of online pharmacy, telemedicine and marketplace with strong brands in Germany and other European countries. Deliveries are mainly from the highly automated logistics centre in Heerlen, the Netherlands. TeleClinic is Germany’s largest telemedicine platform, connecting patients with more than 6,500 doctors. DocMorris operates leading marketplaces for health and personal care products in Southern Europe. With its broad range of products and services, DocMorris is pursuing its vision of becoming the leading digital health companion for everyone to manage their health in one click. Around 1,600 employees in Germany, the Netherlands, Spain, France, Portugal and Switzerland generated an external revenue of CHF 1,186 million serving over 12 million active customers in 2025. The shares of DocMorris AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker DOCM). For further information, please visit corporate.docmorris.com.

Disclaimer
This announcement contains certain forward-looking statements about DocMorris AG and its business, either explicitly or implicitly. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results, financial position, performance or achievements of DocMorris AG to differ materially from the future results, performance or achievements expressed or implied by such forward-looking statements. DocMorris AG is making this announcement available as of today’s date and undertakes no obligation to update the forward-looking statements contained herein as a result of new information, future events or for any other reason.

 

 

^[1] External revenue consists of the revenue of DocMorris plus online revenue of apotal, less revenue related to supplies to apotal.

^[2] All percentages are in local currency.

^[3] Consisting of OTC business and Digital Services (TeleClinic, Retail Media, Marketplace).

^[4] Customers supplied by DocMorris, either directly or through its partners.

Heidelberg Pharma Reports on the First Nine Months of Financial Year 2026

• Phase IIa trial in multiple myeloma at the recommended Phase II dose (RP2D) of 175 µg/kg proceeding as planned
• NMPA approval for clinical trial of pamlectabart tismanitin (HDP-101) combination therapy in China
• Additional collaboration agreement signed with Huadong Medicine to jointly develop new Antibody Drug Conjugates
• New preclinical and clinical data presented at scientific meetings
• Financial figures in line with planning; Sales revenue and other income increased by 79% compared to previous year and cost reduction program successfully implemented with total cost savings of roughly 30%

Ladenburg, Germany, 15 October 2026 – Heidelberg Pharma AG (FSE: HPHA) reported today on its operational progress as well as on the Group’s financial figures for the first nine months of fiscal year 2026 (1 December 2025 – 31 August 2026).

Dr. Dongzhou Jeffery Liu, Chief Executive Officer of Heidelberg Pharma AG, commented: “The first nine months of fiscal year 2026 have been a period of important progress for Heidelberg Pharma. We have advanced the clinical development of our lead project HDP-101 (pamlectabart tismanitin), strengthened our financial position and rebuilt our early ADC pipeline through our strong strategic partnership with Huadong Medicine. In our lead program pamlectabart tismanitin, we have achieved a development milestone by obtaining the recommended Phase II dose (RP2D) of 175 µg/kg and are currently focused on advancing the clinical Phase IIa study in heavily pretreated multiple myeloma patients in Europe and the United States to generate further clinical data. Patient recruitment is progressing as planned, and we are seeing increased interest from investigators following the demonstration of a favorable safety profile and initial encouraging efficacy data for our Amanitin-based ADC. We are actively seeking potential partnerships with our three lead assets (clinical or clinical-ready stage) aiming to fast develop these drug candidates and demonstrate the clinical benefits to the cancer patients who need them.

At the same time, we are very proud to have recently received approval, together with Huadong Medicine, to conduct a combination study with pamlectabart tismanitin in China, which will be carried out by our partner.”

Peter Willinger, Chief Financial Officer of Heidelberg Pharma AG, commented: “We are convinced that the new collaboration agreement with Huadong will increase our added value and contribute to the future growth of the Company. Next to that our partner programs continue to progress as planned and generated milestone payments in the first nine months. Together with the royalty financing agreement with HealthCare Royalty and Soleus Capital, this reinforces our solid financial position and supports the confirmation of our 2026 financial guidance. Furthermore, the decrease in expenses is a result of the stringent cost savings in the last months, which will remain a focus in the future.”

Key operational developments within the company and among its partners

• Pamlectabart tismanitin (HDP-101) development program: Pamlectabart tismanitin (HDP-101), an Amanitin-based antibody-drug conjugate (ADC) targeting the BCMA antigen, is being tested in a Phase I/IIa open-label, multicenter study for the treatment of relapsed or refractory multiple myeloma, a cancer of the bone marrow. The Phase I dose escalation part of the clinical study was completed in April 2026, after treating ten patient cohorts across a dose range of 20 to 218 µg/kg. Heidelberg Pharma’s Benefit and Risk Assessment team agreed with the recommendation of the study’s Safety Review Committee (SRC), which had conducted a comprehensive review of safety, tolerability and pharmacokinetic (PK) data from the ongoing trial, and selected the dose level from Cohort 9 – 175 µg/kg – as Recommended Phase 2 Dose (RP2D).
  In the Phase I part of the study, 53 patients with relapsed or refractory multiple myeloma (RRMM) were dosed and included in the data analysis. All patients were heavily pretreated with a median of five prior lines of treatment. Pamlectabart tismanitin was well-tolerated and a maximum tolerated dose was not reached. All adverse events that occurred were reversible, and no treatment related grade 5 events were observed.
  In clinical Phase 1 study, clinical responses were observed from ≥90 µg/kg, with increasing efficacy at higher doses. Across Cohorts 5 – 9 (90 -175 µg/kg), the Overall Response Rate (ORR) was 42% (13 out of 31 evaluable patients), including seven partial responses (PR), three very good partial responses (VGPR), and three stringent complete responses (sCR). In Cohort 9 (175 µg/kg), two out of five evaluable patients achieved good response: one PR and one VGPR.
• New preclinical data from the ATAC technology platform presented at the AACR 2026 Annual Meeting: Heidelberg Pharma presented promising preclinical data from its Amanitin-based ADC HDP-103 targeting metastatic castration‑resistant prostate cancer (mCRPC) at the American Association of Cancer Research (AACR) Annual Meeting 2026 in April.
  HDP-103 demonstrated target-specific binding in human tissues and robust and durable antitumor activity in patient-derived xenograft (PDX) models. The potent anti-tumor efficacy of HDP-103, combined with a favorable half-life and a manageable safety profile, led to a comfortable therapeutic index (TI) of HDP-103 that is well in the range of other ADCs that are approved or in development for solid tumor indications. Taken together, these data warrant further clinical development of HDP-103 as a novel treatment option for mCRPC.
• Milestone payment from partner Takeda received: Partner Takeda has started clinical development of its ADC candidate (TAK-188), which utilizes the Amanitin-based ADC technology licensed from Heidelberg Pharma. With the dosing of the first patient in a Phase I/II clinical trial in patients with advanced or metastatic solid tumors, an agreed-upon development milestone was reached in January, triggering a payment to Heidelberg Pharma. Financial details were not disclosed.
• Milestone payment from partner Huadong received, programs on track: Strategic partner Huadong Medicine dosed the first patient in a clinical trial with pamlectabart tismanitin in China in March, hereby achieving an agreed-upon development milestone that triggered a payment to Heidelberg Pharma.
  The Phase I clinical trial will evaluate the safety, tolerability, pharmacokinetics and efficacy of pamlectabart tismanitin in Chinese patients with plasma cell disorders, including multiple myeloma. This bridging study is conducted in addition to the existing clinical program with this ATAC to ensure comparability of safety and efficacy across different populations. Dosing has been initiated at 140 µg/kg, a dose level previously shown to be safe and well tolerated in the Caucasian ethnicity.
  Furthermore, at the end of August it was announced that the China National Medical Products Administration (NMPA) has granted Clinical Trial Approval for a Phase Ib/II clinical trial evaluating pamlectabart tismanitin in combination therapy for the treatment of patients with relapsed/refractory multiple myeloma.
  This trial will evaluate the safety, tolerability, and preliminary efficacy of pamlectabart tismanitin in combination either with pomalidomide and dexamethasone, or with daratumumab and dexamethasone, in adult patients with relapsed/refractory multiple myeloma who have received at least one prior line of therapy. The trial will be conducted by Heidelberg Pharma’s partner Huadong Medicine in China who will bear the development cost.
• Additional collaboration agreement signed with Huadong Medicine to jointly develop new Antibody Drug Conjugates: Heidelberg Pharma and Huadong Medicine have broadened their existing partnership through joint research and development of new ADCs involving up to six targets. Under the agreement, the parties will combine and leverage their complementary technologies, expertise, and resources. This includes Heidelberg Pharma’s proprietary ATAC technology platform and other novel toxin payloads, together with Huadong’s state-of-the-art R&D capabilities. The partnership aims to create synergies and drive the development of innovative next-generation ADCs, including bispecific and multispecific ADCs.
  The new ADCs may incorporate proprietary antibodies or technologies from Huadong Medicine and may carry dual payloads. This combination is designed to improve the targeting precision and safety of the drugs, while enhancing biological efficacy and clinical benefits, thereby offering potentially transformative therapeutic options for patients with relapsed/refractory diseases. The agreement foresees that ownership of the resulting development candidates will be allocated between the partners, taking into account their respective contributions.
• Amendment to license agreement with HealthCare Royalty secures USD 20 million: In early March, a further amendment to the existing license agreement with HealthCare Royalty (HCRx), with the participation of Soleus Capital Management, L.P. (Soleus Capital), was signed. The amended agreement covers the partial monetization of Heidelberg Pharma’s future royalty payments from the global sale of Telix’s diagnostic imaging agent TLX250-Px (proposed trade name: Zircaix^®). In connection with the amendment, Heidelberg Pharma received USD 20 million from Soleus Capital upfront. An additional payment of USD 25 million from Soleus Capital will be due upon FDA approval of TLX250-Px.
  As part of the current contract extension, Heidelberg Pharma has agreed to an increase in the cap on total payments as well as certain other contractual amendments. Soleus Capital’s participation has no impact on the payment from HCRx upon FDA approval.
• Change in Executive Management Board: Chief Financial Officer Walter Miller left the Company at the end of April 2026 upon expiration of his contract and at his own request. Peter Willinger succeeded him as Chief Financial Officer effective 1 May 2026.

Events after the end of the reporting period

• New clinical data on pamlectabart tismanitin (HDP-101) presented at International Myeloma Society Annual Meeting 2026: At the Annual Meeting of the International Myeloma Society (IMS) in Glasgow, United Kingdom, in mid-September, Professor Marc Raab, Head of the Heidelberg Myeloma Center at Heidelberg University Hospital, Germany, presented new clinical data from ten patient cohorts in the ongoing study evaluating pamlectabart tismanitin in multiple myeloma. In cohorts 9 and 10, pamlectabart tismanitin consistently demonstrated a very good safety and tolerability profile. In Cohort 9 (175 µg/kg), encouraging signs of clinical efficacy were seen as two out of five evaluable patients achieved good response: one PR and one VGPR.

Results of operations, financial position and net assets

The Heidelberg Pharma Group, as of the reporting date consisting of Heidelberg Pharma AG and its three subsidiaries Heidelberg Pharma Research GmbH, HDP G250 AG & Co. KG, and HDP G250 Beteiligungs GmbH, reports consolidated figures. The two latter companies are not operationally active and affiliated to the parent company like Heidelberg Pharma Research GmbH.

The reporting period referred to below relates to the period from 1 December 2025 to 31 August 2026 (9M 2026).

In the first nine months of the 2026 financial year, the Group generated sales revenues and other income totaling EUR 11.5 million (previous year: EUR 6.4 million). This represents an increase of 79.4% and is in line with the planning. The sales revenues included in this figure rose from EUR 1.4 million the previous year to EUR 9.3 million due to milestone payments from partners. Other income amounted to EUR 2.2 million and was thus significantly lower than the previous year’s level of EUR 5.0 million – a figure that was largely driven by unrealized foreign exchange rate gains (EUR 3.4 million).

Operating expenses, including depreciation, decreased by 29.4% to EUR 19.9 million in the reporting period (previous year: EUR 28.2 million), reflecting the restructuring and disciplined cost management. Operating expenses are broken down as follows: Cost of sales increased to EUR 1.7 million (previous year: EUR 0.2 million) because of material deliveries to partners and corresponds to 9% of total costs. Research and development costs of EUR 13.3 million were significantly lower compared to last year (9M 2025: EUR 21.0 million). This decrease by 36.7% reflects the Company’s focus on the leading clinical program. R&D costs continue to represent the largest cost item, accounting for 67% of operating expenses. Administrative costs, which include the costs of holding activities, the stock exchange listing and the executive management board, decreased to EUR 4.3 million compared to the same period last year (EUR 5.0 million), which is mainly due to lower personnel costs. Administrative costs account for 21% of operating expenses. Other expenses for business development, marketing and commercial market supply activities, which mainly include personnel, but also expenses for exchange rate differences, decreased by more than half compared to the previous year from EUR 2.0 million to EUR 0.7 million and represented 3% of operating expenses.

The financial result, which is mainly made up of interest income on bank balances, amounted to EUR 0.2 million (previous year: EUR 0.7 million). The decrease is attributable to a lower investment volume and lower interest rates.

The net loss for the first nine months of the financial year decreased significantly to EUR 8.7 million compared to the previous year’s figure of EUR 21.1 million. This 58.8% improvement was mainly driven by higher revenues and lower operating expenses. Earnings per share improved accordingly from EUR -0.45 in the previous year to EUR -0.19 in the reporting period.

Cash amounted to EUR 19.8 million at the end of the third quarter (30 November 2025: EUR 15.0 million; 31 August 2025: EUR 22.9 million). Excluding financing effects (essentially HCRx/ Soleus Capital), Heidelberg Pharma recorded an average cash outflow of EUR 1.3 million per month in the first nine months of the fiscal year (previous year: EUR 2.8 million outflow).

Total assets as of 31 August 2026 amounted to EUR 42.8 million and were therefore above the figure at the comparative reporting date of 30 November 2025 (EUR 38.1 million). Equity decreased to EUR -19.3 million as a result of the loss for the period compared to the end of the 2025 financial year (EUR -10.9 million).

Financial outlook for 2026

Heidelberg Pharma confirms the full-year financial guidance issued on 26 March 2026.

The Executive Management Board expects the Heidelberg Pharma Group to generate between EUR 11.0 million and EUR 15.0 million in sales revenue and other income in the 2026 fiscal year.

Operating expenses are estimated between EUR 25.0 million and EUR 29.0 million. In addition, Heidelberg Pharma assumes that over the next few years total expenses will continue to exceed income.

If income and expenses develop as anticipated, the change in cash funds in the 2026 fiscal year for Heidelberg Pharma AG’s business operations is expected to remain stable or decline slightly compared to 2025 (EUR -14.4 million). The change in cash funds could therefore be in the range of EUR 0.0 million to EUR -4.0 million. Thus, the cash balance at the end of the 2026 fiscal year should amount to between EUR 11.0 million and EUR 15.0 million (2025: EUR 15.0 million).

The Group’s financing is secured at least until mid-2027 based on current internal planning.

The complete set of figures for the interim financial statements is available at http://www.heidelberg-pharma.com/ “Press & Investors > Announcements and Reports > Financial Reports > Interim announcement of 15 October 2026”. A conference call on this interim announcement will not be offered.

Key figures for the Heidelberg Pharma Group

In EUR thsd.	9M 2026 1 EUR thsd.	9M 2025 1 EUR thsd.
Earnings
Sales revenue	9,297	1,436
Other income	2,228	4,988
Operating expenses	(19,936)	(28,179)
of which research and development costs	(13,311)	(21,042)
Operating result	(8,411)	(21,756)
Earnings before tax	(8,251)	(21,054)
Net loss for the period / Comprehensive income	(8,676)	(21,054)
Basic earnings per share in EUR	(0.19)	(0.45)
Balance sheet as of the end of the period
Total assets	42,819	54,052
Cash	19,841	22,869
Equity	(19,323)	10,530
Equity ratio2 in %	(45.1)	19.5
Cash flow statement
Cash flow from operating activities	(12,360)	(24,818)
Cash flow from investing activities	682	(179)
Cash flow from financing activities	16,645	18,428
Cash flow from other matters	(103)	15.7
Employees (number)
Employees as of the end of the period3	35	126
Full-time equivalents as of the end of the period3	33	114

 

1 The reporting period begins on 1 December and ends on 31 August.
2 Equity / total assets
3 Including members of the Executive Management Board
Rounding of exact figures may result in differences.

Contact Heidelberg Pharma AG Sylvia Wimmer Senior Director Corporate Communications Tel.: +49 6203 1009 1004 Email: investors@hdpharma.com Wallstadter Straße 59, 68526 Ladenburg

IR/PR support MC Services AG Katja Arnold (CIRO) Managing Director & Partner Tel.: +49 89 210 228 40 Email: katja.arnold@mc-services.eu

About Heidelberg Pharma

Heidelberg Pharma is the first company to develop cancer therapies using Amanitin, a compound derived from the green death cap mushroom. The biological mechanism of action of the toxin represents a new therapeutic modality and is used as a compound in the Amanitin-based ADC technology, the so-called ATAC technology.

The lead candidate HDP-101 (INN: pamlectabart tismanitin) is a BCMA ATAC in clinical development for multiple myeloma. The candidate has been granted Orphan Drug Designation and Fast Track Designation from the FDA. A second ATAC candidate, HDP-102, is in clinical development stage in Non-Hodgkin Lymphoma. HDP-103 against metastatic castration-resistant prostate cancer and HDP-104 targeting gastrointestinal tumors such as colorectal cancer have completed preclinical development. These programs are available for partnering.

The company is based in Ladenburg, Germany, and is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA. More information is available at www.heidelberg-pharma.com/.

ATAC^® is a registered trademark of Heidelberg Pharma Research GmbH.

This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will”, “should”, “future”, “potential” or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

Düsseldorf, 14 October 2026 – The Supervisory Board of Douglas AG today resolved to appoint Jean-Marc Bellaiche as a member of the Management Board and Chief Executive Officer (CEO) of Douglas AG with effect from 1 November 2026. The appointment is for a term of four years. Mr. Bellaiche succeeds Alexander van der Laan, who has decided to retire from active management. Mr. van der Laan will resign from his office as member and Chief Executive Officer of the Management Board by mutual agreement with the Supervisory Board with effect from 31 October 2026.
 

Change in Top Management
Jean-Marc Bellaiche to become new CEO of the DOUGLAS Group – Sander van der Laan to retire

Düsseldorf, 14 October 2026 – Jean-Marc Bellaiche will become the new Chief Executive Officer (CEO) of Europe’s leading premium beauty retailer, the DOUGLAS Group. He succeeds Sander van der Laan, who, after a career of 36 years in the international retail business including four years with the DOUGLAS Group, has decided to retire as an executive. The Supervisory Board of Douglas AG today appointed Jean-Marc Bellaiche as CEO with effect from 1 November 2026 for a term of four years.

“This important change in the leadership at the top of the company has been prepared very thoughtfully and carefully, ensuring a smooth and professional transition”, said Dr. Henning Kreke, Chairman of the Supervisory Board of the Douglas AG. “We truly regret Sander van der Laan’s decision to retire, while fully respecting his choice after a long and successful career. With his departure, the DOUGLAS Group loses an outstanding leader and highly experienced retail executive who has played a pivotal role in the successful development of the Group. At the same time, we are very pleased to have appointed Jean-Marc Bellaiche, a highly experienced executive in international retail and luxury, with a strong track record across beauty, premium department stores, digital transformation, brand building and strategy. We are convinced that he will build on the progress already made and put even more focus on customer-centricity, beauty brand partnerships and operational excellence.”

“I would like to thank the Supervisory Board of the Douglas AG for the confidence it has placed in me”, said Bellaiche. “I am particularly excited to join the Group at such an important moment in the evolution of the beauty industry. The DOUGLAS Group plays a leading role in the European premium beauty market and has a manifold of unique assets, including an outstanding omnichannel footprint, a large base of loyal customers, and an attractive assortment based on close relationships with beauty brands. I look forward to building on these strengths together with the management team and all my colleagues across 22 European countries, while driving the innovations and changes needed to succeed in a rapidly changing market environment.”

Van der Laan said: “I am incredibly grateful for my time at the DOUGLAS Group. I have met many inspiring people, learned a great deal about premium beauty, and, together with around 20,000 colleagues, we have made significant progress. The decision to step down was not an easy one for me. But after a 36-year career, including senior leadership roles at highly respected retail companies in Europe and the United States, I feel that the time is right to retire from executive management. This is the right moment to hand over the reins to someone who can bring fresh thinking and new ideas.”

The 56 year old Frenchman Bellaiche began his career at Boston Consulting Group in 1993, where he eventually became Managing Director and Global Leader of the Luxury, Fashion and Beauty sector. In 2014, he joined Tiffany & Co. as Senior Vice President and member of the Executive Committee. He subsequently held senior leadership and board positions in the technology companies Contentsquare and Arianee. After spending a decade in the United States, he moved back to Europe in 2020 to become CEO of Printemps Group, which includes the iconic French department store chain. During his five-year mandate, he strengthened Printemps’s distinctiveness and customer-centricity, introduced more exclusivities in the assortment, accelerated its international and omnichannel development, and improved the operating profitability. For the last year, he served as CEO of the luxury resort operator Sani/Ikos Group.

Sander van der Laan joined the DOUGLAS Group in October 2022. Since then, he has successfully driven the transformation of the Düsseldorf-based company into a true omnichannel business and implemented significant strategic, operational, and structural improvements. Among his key achievements are a new category and exclusive-brands strategy and a comprehensive update of the store-format and -network strategy. He also comprehensively reorganized the Group‘s supply chain, further developed the digital platforms, implemented a comprehensive ESG strategy, and harmonized internal processes and structures. In 2024, the company was listed on the stock exchange. Van der Laan has also been deeply committed to further developing the corporate culture and introduced the purpose ‘Make life more beautiful’.

Dr. Kreke said: “On behalf of the entire Supervisory Board, I would like to thank Sander van der Laan for his outstanding achievements and dedication to the company. We wish him all the best for this new chapter in his life. We also wish Jean-Marc Bellaiche a successful start in his new role at the DOUGLAS Group and look forward to working with him as he leads the company together with CFO Marco Giorgetta, the entire management team and all employees into its next phase of development.”

About the DOUGLAS Group

The DOUGLAS Group, with its commercial brands DOUGLAS, NOCIBÉ, Parfumdreams and Niche Beauty, is the number one omnichannel premium beauty destination in Europe. The DOUGLAS Group is inspiring customers to live their own kind of beauty by offering a unique assortment online and in around 1,970 stores. With unparalleled size and access to customers, the DOUGLAS Group is the partner of choice for brands and offers a premium range of selective and exclusive brands as well as own corporate brands. The assortment includes fragrances, color cosmetics, skin care, hair care, accessories as well as beauty services. Strengthening its successful omnichannel positioning while consistently developing superior customer experience is at the heart of the DOUGLAS Group strategy “Let it Bloom”. The winning business model is underpinned by the Group’s omnichannel proposition, leading brands, and data capabilities. In the financial year 2024/2025, the DOUGLAS Group generated sales of 4.58 billion euros and employed more than 19,900 people across Europe. The DOUGLAS Group (Douglas AG) is listed at the Frankfurt Stock Exchange.

For further information please visit the DOUGLAS Group Website.

Presse Contact

Peter Wübben
SVP Group Communications & Sustainability
Phone: +49 211 16847 6644
Mail: newsroom@douglas.de

Investor Contact

Dafne Sanac
Director / Senior Principal Investor Relations

Phone: +49 151 55675545
E-Mail: ir@douglas.de

Ad-hoc notification in accordance with Sec. 17 of the MAR

Drägerwerk AG & Co. KGaA: Preliminary figures Q3 2026: Earnings below prior year – net sales up – forecast confirmed

Lübeck, October 14, 2026 – Based on preliminary calculations, Dräger generated earnings before interest and taxes (EBIT) of around EUR 48 million in the third quarter of 2026 (Q3 2025: EUR 56.7 million). This includes customs duty refunds of EUR 20.1 million. The EBIT margin came to around 5.6 percent (Q3 2025: 6.8 percent).

The lower net sales growth in the third quarter of 2026 was offset by a disproportionate increase in functional expenses. At the same time, the comparison base was high: In the third quarter of 2025, EBIT more than doubled due to significant net sales growth driven by catch-up effects and moderate cost development.

Net sales increased by 1.0 percent (net of currency effects; nominal: 2.1 percent) to around EUR 851 million in the third quarter of 2026 (Q3 2025: EUR 833.3 million). Net sales in the safety division rose by 4.1 percent (net of currency effects; nominal: 5.3 percent) to around EUR 381 million (Q3 2025: EUR 362.0 million). In the medical division, net sales declined by 1.4 percent (net of currency effects; nominal: -0.4 percent) to around EUR 469 million, ending slightly below the prior-year level (Q3 2025: EUR 471.3 million). The Group’s gross margin increased to around 47.5 percent (Q3 2025: 45.6 percent). The main reason for this was the customs duty refunds.

Order intake rose by 7.0 percent (net of currency effects; nominal: 8.2 percent) to around EUR 926 million (Q3 2025: EUR 856.1 million). The main growth driver was safety, with a strong increase of 20.2 percent (net of currency effects; nominal: 21.7 percent) to around EUR 452 million (Q3 2025: EUR 371.4 million). This development was due in particular to high demand in the regions Germany, Americas, and Asia-Pacific. In medical, order intake fell by 3.0 percent (net of currency effects; nominal: -2.2 percent) to around EUR 474 million (Q3 2025: EUR 484.7 million).

Business performance in the first nine months of 2026
In the first nine months, order intake of around EUR 2,674 million was 3.6 percent (net of currency effects; nominal: 3.1 percent) above the prior-year figure (9 months 2025: EUR 2,594.1 million). The safety division recorded significant growth of 13.1 percent (net of currency effects; nominal: 13.1 percent) to around EUR 1,243 million, thanks to overall very good demand (9 months 2025: EUR 1,098.6 million). In the medical division, order intake decreased by 3.5 percent (net of currency effects; nominal: -4.3 percent) to around EUR 1,431 million (9 months 2025: EUR 1,495.5 million). The main reason for this was the major order from Mexico for hospital infrastructure systems in the second quarter of 2025. Adjusted for this effect, order intake in medical would have increased slightly (net of currency effects) in the first nine months of 2026.

Net sales rose by 5.3 percent (net of currency effects; nominal: 4.7 percent) to around EUR 2,454 million (9 months 2025: EUR 2,343.5 million). Both divisions contributed to this increase: The safety division recorded growth of 6.5 percent (net of currency effects; nominal: 6.4 percent) to around EUR 1,087 million (9 months 2025: EUR 1,021.2 million), while medical recorded an increase of 4.4 percent (net of currency effects; nominal: 3.4 percent) to around EUR 1,367 million (9 months 2025: EUR 1,322.3 million). The Group’s gross margin went up to around 46.8 percent (9 months 2025: 45.1 percent).

EBIT increased by almost half to around EUR 112 million (9 months 2025: EUR 77.1 million). The EBIT margin also improved significantly to around 4.6 percent (9 months 2025: 3.3 percent). EBIT included one-off effects of EUR 27.9 million from refunded customs duties. Of this amount, EUR 7.8 million was attributable to the second quarter and EUR 20.1 million to the third quarter. Part of these refunds – EUR 3.8 million in total – relates to customs payments from the current fiscal year and is therefore recognized with no impact on earnings.

Forecast for 2026
Dräger confirms its forecast for the current fiscal year and continues to expect an increase in net sales of 2.0 to 6.0 percent (net of currency effects) and an EBIT margin of 6.0 to 8.0 percent.

The quarterly statement will be published on October 29, 2026.

 

Drägerwerk AG & Co. KGaA
Moislinger Allee 53–55
23558 Lübeck, Germany
www.draeger.com

 

Investor Relations:
Thomas Fischler
Tel. +49 451 882-2685
thomas.fischler@draeger.com

 

Corporate Communications:
Ulrike Abratis
Tel. +49 451 882-3202
ulrike.abratis@draeger.com

 

Disclaimer
This ad hoc report contains statements on the future development of Dräger Group. These forward-looking statements are based on the current expectations, presumptions, and forecasts of the Executive Board as well as the information available to date. They were compiled to the best of the company’s knowledge. Dräger does not provide any warranty nor assume any responsibility for the future developments and results described above. These are dependent on a number of factors. They entail various risks and contingencies outside of the company’s influence and are based on assumptions which could prove to be incorrect. Dräger does not assume any responsibility for updating the forward-looking statements contained in this report. This does not infringe any legal stipulations on the adjustment of forecasts. Please go to Investor Relations / Definitions of financial indicators at www.draeger.com for information on alternative performance measures used.

seragy Launches with €12 Million Financing to Advance Quantitative Biomarkers
for Neurodegenerative Diseases

• Development of quantitative biomarker strategies for proteopathies through seragy’s proprietary SeRAS^® technology
• Expansion of the company’s laboratory and analytical capabilities with funding from Commerzbank, the Mittelständische Beteiligungsgesellschaft (MBG), and the State of Lower Saxony
• Separate funding from The Michael J. Fox Foundation provides support for a quantitative SeRAS-based assay for Parkinson’s disease

Hanover, Germany, October 14, 2026 – seragy holding GmbH (formerly Prosperodes GmbH), a biomarker strategy company focused on neurodegenerative diseases and other proteopathies, has secured €12 million in funding to accelerate the development of its SeRAS^® platform (Seed Replication, Analysis and Subtyping) and expand its laboratory and analytical capabilities. The financing is backed by Commerzbank, the Mittelständische Beteiligungsgesellschaft (MBG), and the State of Lower Saxony.

Proteopathies – such as Alzheimer’s, Parkinson’s, and ALS – are among the greatest challenges in modern medicine. These diseases are characterized by pathological protein aggregation and display substantial molecular heterogeneity, often with multiple distinct disease subtypes within one indication. Current technologies often lack the ability to distinguish clinically relevant molecular patterns and quantify aggregation processes with the precision required for translational drug development.

Using its proprietary SeRAS technology, seragy develops quantitative, mechanism-relevant biomarkers that generate molecular fingerprints of pathological protein aggregation from patient samples. Unlike conventional seed amplification assays, which primarily provide binary detection without molecular resolution, these fingerprints will reveal quantitative biological changes and identify relevant subtypes of proteopathies. By translating aggregation biology into actionable biomarker insights, seragy will support pharmaceutical and biotechnology partners in developing more targeted therapeutic strategies from early discovery through clinical development.

“This financing provides the foundation for us to transform how pathological protein aggregation is measured and understood,” said Dr. Thorsten Lührs, Managing Partner for Strategy & Innovation and Co-Founder of seragy. “Together with our highly qualified interdisciplinary team, we will continue advancing SeRAS as a next-generation biomarker platform that makes aggregation processes measurable and biologically interpretable. Through our global collaborations with pharmaceutical and biotechnology partners, SeRAS provides insights informing therapeutic strategies and helps accelerate the development of effective treatments for patients with proteopathies. We thank Commerzbank, the MBG, and the State of Lower Saxony for their trust and commitment to our technology.”

With this combination of debt financing, equity capital, and public funding, seragy will accelerate the further development and application of its SeRAS technology by expanding its laboratory and analytical capabilities and growing its team in Hanover. At the same time, the company will strengthen its presence in European and international markets and further expand its collaborations with pharmaceutical and biotechnology companies to provide translational biomarker strategies across early-stage discovery, preclinical, and clinical development.

“seragy combines scientific excellence and a clear vision with a highly innovative technology platform for addressing a critical challenge in developing treatments for neurodegenerative diseases,” said Marc Hülsbruch, Chairman of the Management Board for Small-Business Customers in Lower Saxony at Commerzbank AG. “By advancing cutting-edge technologies that ultimately help patients, companies like seragy demonstrate how a strong innovation ecosystem in Lower Saxony can contribute to the future of healthcare worldwide.”

Separately, seragy is one of five recipients of funding from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through its Seed Amplification Assay Innovation Program. The grant supports the development and evaluation of a quantitative biomarker assay for Parkinson’s disease and underscores the potential of the SeRAS technology to advance the development of translational biomarkers in neurodegenerative diseases.

About seragy holding GmbH

seragy holding GmbH (formerly Prosperodes GmbH) is a biomarker strategy company based in Hanover, Germany. Through its wholly owned subsidiary seragy analytics GmbH and using its proprietary SeRAS® platform, the Company develops quantitative translational biomarkers for proteopathies – diseases driven by protein aggregation – including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). Seragy’s strategy is to generate molecular fingerprints of protein aggregates, which will reveal disease-specific subtypes and enable quantification of biological changes. The goal is to accelerate the development of targeted therapies through deep insights into disease mechanisms and to improve the chances of success for new drugs through precise biomarkers.

Founded in 2022 as Prosperodes GmbH, seragy holding GmbH is led by Dr. Christiane Ritter and Dr. Thorsten Lührs, two scientists with nearly three decades of expertise in protein aggregation research, alongside Arne Ungruh, an experienced business and finance leader. The holding company owns the intellectual property, acts as the licensor and consolidates central holding functions, while operational activities, particularly services and projects for partner companies, are carried out by seragy analytics GmbH. The company is supported by The Michael J. Fox Foundation, Commerzbank AG, Mittelständische Beteiligungsgesellschaft Niedersachsen (MBG), and the State of Lower Saxony, among others.

For more information, visit: https://seragy.com/

About SeRAS^®

SeRAS^® (Seed Replication, Analysis, and Subtyping) is seragy’s proprietary technology platform for the highly sensitive analysis of pathological protein aggregates. As a further development of classical seed amplification assays, SeRAS combines seeding-based biochemistry with high-sensitivity optics, automated data analysis, software algorithms, and micromechanical components. At the heart of the platform is the MetisOne^® Analyzer, which has been designed to enable quantitative and reproducible measurements of protein aggregates from patient samples. Unlike conventional seed amplification assays, which primarily provide qualitative detection, SeRAS has been developed to generate quantitative molecular fingerprints that can be used to characterize aggregation patterns, distinguish molecular subtypes, and track biological changes over the course of a disease. The platform is designed for the development of translational biomarkers, from early drug discovery through preclinical and clinical development.

 

seragy Contact: seragy holding GmbH                                                                  info@seragy.com

Media Contact: MC Services AG Dr. Cora Kaiser / Dr. Regina Lutz Tel.: +49 (0)89 210 228 0 E-Mail: seragy@mc-services.eu

Gerresheimer Improves its EcoVadis Rating and is once again awarded Gold

• Gerresheimer among the top 5% of all rated companies
• Overall score increased to 82 out of 100 points
• Ranked in the top 1% in sustainable procurement

Duesseldorf, October 14, 2026. Gerresheimer, an innovative system and solution provider and a global partner for the pharma, biotech and cosmetic industries, has once again been awarded Gold by the sustainability rating provider EcoVadis. EcoVadis evaluates the management systems of companies worldwide in the categories of environment, labor and human rights, ethics, and sustainable procurement. More than 175,000 companies are evaluated by EcoVadis each year. In the latest rating, Gerresheimer increased its score from 78 (2025) to 82 out of 100 points. This places Gerresheimer among the top 5% of all companies rated by EcoVadis and within the top 2% in its industry. With this rating result, Gerresheimer underscores its progress in consistently implementing its sustainability targets.

“With the improved EcoVadis rating and our first voluntary report based on the CSRD, we are making our sustainability performance measurable and transparent for our customers,” explains Wolf Lehmann, CFO of Gerresheimer AG. “We remain committed to consistently pursuing our ambitious sustainability targets in the future.”

Gerresheimer among the top 2% in its industry
Since 2011, Gerresheimer has relied on EcoVadis to have its sustainability management independently assessed across four different dimensions. In 2022, Gerresheimer achieved Gold status for the first time with a score of 68 out of 100 points and continued to improve its overall rating in the following years. In 2026, the company once again increased its score to 82 out of 100 points, placing Gerresheimer not only among the top 5% of all companies evaluated by EcoVadis but also within the top 2% in the industry. Gerresheimer performs particularly well in the area of sustainable procurement. Here, Gerresheimer ranks among the top 1% in the industry, underscoring the importance of responsible supply chains for its own sustainability performance.

Internationally recognized sustainability rating
EcoVadis’ comprehensive Corporate Social Responsibility (CSR) assessment framework is based on internationally recognized standards such as the UN Global Compact, the conventions of the International Labor Organization (ILO), the standards of the Global Reporting Initiative (GRI), the ISO 26000 standard, the CERES Principles, and the UN Guiding Principles on Business and Human Rights. The EcoVadis rating thus covers a wide range of information on companies performance in the areas of the environment, labor and human rights, ethics, and sustainable procurement, while taking industry-specific characteristics into account.

Ambitious sustainability targets
Gerresheimer has set ambitious goals to achieve measurable progress in the areas of climate protection, the circular economy, responsible supply chains, and social responsibility. With clear performance indicators, transparent reporting, and independent assessments, Gerresheimer ensures that progress is documented comprehensively and can be compared with international benchmarks.

For the 2025 financial year, Gerresheimer has, for the first time, voluntarily submitted an audited, non-financial consolidated report based on the Corporate Sustainability Reporting Directive (CSRD). In doing so, the company has significantly advanced the structure of its sustainability reporting. The report is available for download here.

In addition, Gerresheimer discloses relevant data annually on the EcoVadis platform and as part of the CDP rating. MSCI, Sustainalytics, and ISS also evaluate the company’s sustainability performance. An overview of Gerresheimer’s external sustainability assessments is available here.

 

About Gerresheimer 
Gerresheimer is an innovative systems and solutions provider and a global partner for the pharma, biotech and cosmetic industries. The Group offers a comprehensive portfolio of primary packaging solutions including closures and accessories, as well as drug delivery systems, medical devices and solutions for the health industry. The product range includes infusion, dropper and syrup bottles, tablet containers, vials, syringes, pens, auto-injectors, inhalers, ampoules, cartridges, on-body devices as well as digital solutions for therapy support. Gerresheimer ensures the safe delivery and reliable administration of drugs to the patient. Gerresheimer supports its customers with comprehensive services along the value chain and in addressing the growing demand for enhanced sustainability. With 39 production sites in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets. The Group generated revenues of around EUR 2.3bn in 2025 and employs over 13,000 people. Gerresheimer AG is listed on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6).
www.gerresheimer.com

Contact Gerresheimer

Media
Jutta Lorberg Group Senior Director Communication & Marketing T +49 211 6181 264 jutta.lorberg@gerresheimer.com	Dersim Korkmaz Manager Corporate Communication T +49 211 6181 296 dersim.korkmaz@gerresheimer.com
Investor Relations
Guido Pickert Vice President Investor Relations T +49 211 6181 220 gerresheimer.ir@gerresheimer.com

MindMaze Therapeutics Reports New Home-Based Rehabilitation Results Ahead of MindMotion Lite Launch

Multi-site program demonstrates threefold increase in rehabilitation training dose, with 84% delivered independently and significant improvements across functional measures

Geneva, Switzerland – October 14, 2026 – MindMaze Therapeutics (SIX: MMTX), a global leader in scalable precision neurotherapeutics, today announced new real-world evidence from a multi-site program conducted with Vibra Healthcare, presented yesterday at the American Congress of Rehabilitation Medicine (ACRM) in Washington, DC.

The program demonstrated that home-based rehabilitation using MindMotion increased total motor-training dose by a median factor of three compared with usual outpatient therapy alone. 84% of active training was completed independently, without direct therapist supervision. Participants also showed statistically significant improvements in functional independence, balance, mobility and cognition, alongside high patient satisfaction.

Building on previously reported inpatient results with Vibra Healthcare, the findings further support MindMaze Therapeutics’ strategy to extend high-dose, high-intensity neurorehabilitation into patients’ homes. This is particularly relevant to the Company’s upcoming launch of MindMotion Lite, expected by year-end 2026. Recently announced, the tablet-based solution is designed to deliver the full range of MindMotion GO neurotherapeutic activities with substantially reduced hardware requirements, simplifying home deployment and supporting broader adoption by healthcare providers.

“Earlier this year, we showed that MindMaze’s high-dose, high-intensity therapy, integrated into inpatient rehabilitation, delivers superior functional outcomes in a resource-efficient way,” said Zach Henderson, CEO of MindMaze Therapeutics. “Now, we are demonstrating that this value can extend into the home to address a well-recognized gap in care once patients leave the clinic, in line with the 2026 AHA/ASA Guideline for Adult Stroke Rehabilitation and Recovery. These results, combined with our upcoming MindMotion Lite tablet-based solution, will help make high-quality neurotherapeutics more accessible. Together, these milestones bring us closer to our mission of making neurotherapeutics available at scale.”

Study Design and Results
The retrospective, multi-site quality improvement program evaluated 177 rehabilitation episodes involving 172 adults with a range of neurological conditions, primarily stroke, across four Vibra Healthcare outpatient sites, without a control group. Participants followed an eight-week home-training program using MindMotion GO, with an optional four-week extension and periodic therapist supervision.

Key findings included:

• Training dose: Patients completed an average of 174 minutes of active training per week, with 84.4% delivered asynchronously. The additional home training increased total motor-training dose by a median factor of 3.0 compared with usual outpatient therapy alone, based on published assumptions for active practice during usual care.
• Feasibility and engagement: 92.7% successfully completed home setup, while 80.2% achieved the predefined minimum training exposure. Among surveyed participants, 83.8% of satisfaction ratings were positive.
• Functional outcomes: Statistically significant pre–post improvements were observed in independence (Barthel Index: +10.4 points), balance (Berg Balance Scale: +10.5 points), cognition (SLUMS: +3.4 points) and mobility (Timed Up and Go: −8.8 seconds) among participants with available paired assessments.

The full poster, High-Dose, Home-Based Neurorehabilitation Using Gamified Technology: A Multi-Site Quality Improvement Program, is available at mindmazetherapeutics.com/mindmaze-platform/clinical-evidence.

About MindMaze Therapeutics
MindMaze Therapeutics (SIX: MMTX) is a global leader in scalable, precision neurotherapeutics, dedicated to redefining the recovery trajectory for patients around the world. By integrating advanced software, proprietary sensors, and AI-driven data analytics, MindMaze Therapeutics provides a seamless continuum of care from the acute hospital phase to outpatient treatment to home-based therapy. The company’s FDA-listed and CE-marked products are designed to address the systemic shortage of specialized clinicians, offering scalable, reimbursable solutions for stroke, Parkinson’s disease, and other neurological disorders. With an extensive library of rigorous clinical validation, MindMaze Therapeutics is operationalizing the future of neurorestorative medicine. For more information, visit www.mindmazetherapeutics.com.

Media & Investor Contacts
Jeremy Meinen, Chief Financial Officer
ir@mindmazetherapeutics.com

DISCLAIMER
This press release contains forward-looking statements, which may be identified by words such as “believe,” “assume,” “expect,” “intend,” “may,” “could,” “will,” or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. This communication is provided as of the date hereof, and MindMaze Therapeutics undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Ad hoc: Evotec announces preliminary nine-months 2026 results above market expectations, reaffirming full-year 2026 guidance
 

Hamburg, Germany – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced preliminary unaudited financial results for first nine months of 2026. Full financial results for the third quarter and the first nine months of 2026 will be published on November 5, 2026, as scheduled.

Based on preliminary figures, Evotec expects Group revenues for the first nine months of 2026 of approximately €465.0 million and adjusted Group EBITDA of approximately -€42.8 million. These figures are above current market expectations, with the variance driven largely by the phasing of consensus estimates.

Evotec reaffirms its full-year 2026 guidance, which projects Group revenues of approximately €570 to €610 million (€595 to €635 million at CER) and adjusted Group EBITDA of approximately -€70 to -€105 million (-€60 to -€90 million at CER).
 

– End of the ad hoc release –
 

Contact: Dr. Sarah Fakih, EVP Head of Global Communications and Investor Relations, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49 (0) 151 7068 8784 (m), sarah.fakih@evotec.com